HighTower Advisors
HRTX icon

HighTower Advisors’s Heron Therapeutics HRTX Stock Holding History

HighTower Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-500
Closed -$1K – 2466
2019
Q2 		$1K Buy
+500
New +$9.99K ﹤0.01% 2366
2018
Q1 		– Sell
-500
Closed -$2K – 2259
2017
Q4 		$2K Buy
+500
New +$8.15K ﹤0.01% 2236

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

HighTower Advisors's HRTX Position: Q1 2026 in Review

HighTower Advisors increased its Heron Therapeutics (HRTX) stake by 4.9% in Q1 2026, buying an estimated $946 and bringing the position to 17,612 shares worth $14.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3773.

HighTower Advisors first reported a position in HRTX in Q2 2015 and has held it in 31 quarters since. The position peaked at $749K in Q2 2018. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • HighTower Advisors held 17,612 shares of Heron Therapeutics worth $14.1K as of Q1 2026.
  • HighTower Advisors bought 816 Heron Therapeutics shares in Q1 2026, an estimated $946.
  • Heron Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3773 holding.
  • HighTower Advisors first reported a position in Heron Therapeutics in Q2 2015 and has held it in 31 quarters since.
  • HighTower Advisors's Heron Therapeutics position peaked at $749K in Q2 2018.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.